Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Amid struggles of Lilly's Foundayo, injectables still on a roll
Lilly garnered Q2 sales of GLP-1 oral treatment Foundayo at $98 million, coming up far short of rival Novo Nordisk in its launch of GLP-1 pill Wegovy.
Kevin Dunleavy
Aug 5, 2026 11:42am
Novo CEO stands firm on guidance amid Wegovy pill sales onslaught
Aug 5, 2026 11:20am
Inside Noble’s connected approach to patient support
Brought to you by
NOBLE, Inc
Gilead's Yeztugo faces growth outlook questions
Aug 5, 2026 10:44am
What Hub Transitions Really Cost Manufacturers
Brought to you by
Gifthealth
‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters
Aug 5, 2026 10:12am
